First Capital Advisors Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

First Capital Advisors Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$5.7K	Buy	+46	New	+$6.19K	﹤0.01%	643
2018 Q2	–	Sell	-25	Closed	-$4K	–	470
2018 Q1	$4K	Buy	+25	New	+$3.67K	﹤0.01%	667

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

First Capital Advisors Group's JAZZ Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2023: 46 shares worth $5.7K. The stake represents ﹤0.01% of the portfolio and ranks #643 among its holdings. This is a return to the name: First Capital Advisors Group previously reported a position in JAZZ as recently as Q1 2018.

First Capital Advisors Group first reported a position in JAZZ in Q1 2018 and has held it in 2 quarters since. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

First Capital Advisors Group held 46 shares of Jazz Pharmaceuticals worth $5.7K as of Q2 2023.
Jazz Pharmaceuticals was a new First Capital Advisors Group position in Q2 2023.
Jazz Pharmaceuticals made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #643 holding.
First Capital Advisors Group first reported a position in Jazz Pharmaceuticals in Q1 2018 and has held it in 2 quarters since.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.